Clinical Trials Since 2020 of Rapid Anti-suicidal Ideation Effects of Ketamine and Its Enantiomers: a Systematic Review

Overview

Journal Transl Psychiatry

Date 2025 Feb 6

PMID 39915491

Authors

Sumra Sajid

J John Mann

Michael F Grunebaum

Affiliations

Soon will be listed here.

Abstract

Background: Suicide is a global public health problem with few empirically supported treatments.

Methods: We conducted a systematic review of clinical trials (CT) since 2020 of racemic ketamine or one of its enantiomers' (R/S) potential to reduce suicidal ideation or behavior (SIB). An initial PubMed search on April 15th, 2024 yielded 2483 results. 104 relevant CTs were identified. An additional search using other search engines on March 19th, 2024 yielded 52 sources. After screening, 14 RCTs met the inclusion criteria which required clinically significant SIB among participants, ketamine or one of its enantiomers as an anti-SIB treatment, and SIB as an outcome. We excluded neuroimaging studies, meta-analyses, reviews, and case reports. Open-label studies were also excluded except in the case of R-ketamine where we included 2 open trials due to limited published data for this enantiomer, yielding a total of 16 CTs. We used the Revised Cochrane risk-of-bias tool for the RCTs. CTs reviewed had suicidal ideation (SI) but none had suicidal behavior as an outcome.

Results: The studies include ketamine augmentation of other treatments such as electroconvulsive therapy (ECT), various routes of administration - intravenous (IV), intramuscular (IM), and intranasal (IN) - and single versus multiple dose designs. Multiple doses of IV ketamine/S-ketamine produced reductions in SI for periods of several days to weeks, while single doses showed shorter, more variable effects. Multiple and single doses of IN ketamine/S-ketamine and single doses of IV ketamine produced less consistent anti-SI results. IN and IV ketamine/S-ketamine administration appears to be well tolerated. R-ketamine appears to produce fewer side effects, but additional clinical research is needed to clarify its antidepressant and anti-SI effects in humans.

Conclusion: This review affirms the time-limited, anti-SI effects of ketamine and the need for personalized treatment. Limitations include study heterogeneity, small samples, and paucity of data for suicidal behavior or R-ketamine.

References

Cigognini M, Garrudo Guirado A, van de Meene D, Schneider M, Salomon M, de Alexandria V . Intramuscular ketamine vs. escitalopram and aripiprazole in acute and maintenance treatment of patients with treatment-resistant depression: A randomized double-blind clinical trial. Front Psychiatry. 2022; 13:830301. PMC: 9354749. DOI: 10.3389/fpsyt.2022.830301. View

Alphs L, Fu D, Williamson D, Jamieson C, Greist J, Harrington M . SIBAT-A Computerized Assessment Tool for Suicide Ideation and Behavior: Development and Psychometric Properties. Innov Clin Neurosci. 2022; 19(4-6):36-47. PMC: 9341319. View

Liu G, Nguyen B, Lyons B, Sheats K, Wilson R, Betz C . Surveillance for Violent Deaths - National Violent Death Reporting System, 48 States, the District of Columbia, and Puerto Rico, 2020. MMWR Surveill Summ. 2023; 72(5):1-38. PMC: 10208308. DOI: 10.15585/mmwr.ss7205a1. View

Beck A, Kovacs M, Weissman A . Assessment of suicidal intention: the Scale for Suicide Ideation. J Consult Clin Psychol. 1979; 47(2):343-52. DOI: 10.1037//0022-006x.47.2.343. View

Milak M, Rashid R, Dong Z, Kegeles L, Grunebaum M, Ogden R . Assessment of Relationship of Ketamine Dose With Magnetic Resonance Spectroscopy of Glx and GABA Responses in Adults With Major Depression: A Randomized Clinical Trial. JAMA Netw Open. 2020; 3(8):e2013211. PMC: 7424409. DOI: 10.1001/jamanetworkopen.2020.13211. View

Vollenweider F, Leenders K, Oye I, Hell D, Angst J . Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET). Eur Neuropsychopharmacol. 1997; 7(1):25-38. DOI: 10.1016/s0924-977x(96)00042-9. View

Serafini G, Howland R, Rovedi F, Girardi P, Amore M . The role of ketamine in treatment-resistant depression: a systematic review. Curr Neuropharmacol. 2014; 12(5):444-61. PMC: 4243034. DOI: 10.2174/1570159X12666140619204251. View

Bonaventura J, Lam S, Carlton M, Boehm M, Gomez J, Solis O . Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability. Mol Psychiatry. 2021; 26(11):6704-6722. PMC: 8517038. DOI: 10.1038/s41380-021-01093-2. View

Ren L, Chen Q, Gao J, Liu Y, Tao Y, Li X . Clinical efficacy of adjunctive esketamine anesthesia in electroconvulsive therapy for major depressive disorders: A pragmatic, randomized, controlled trial. Psychiatry Res. 2024; 335:115843. DOI: 10.1016/j.psychres.2024.115843. View

10.

Bremner J, Krystal J, Putnam F, Southwick S, Marmar C, Charney D . Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). J Trauma Stress. 1998; 11(1):125-36. DOI: 10.1023/A:1024465317902. View

11.

Fineberg S, Choi E, Shapiro-Thompson R, Dhaliwal K, Neustadter E, Sakheim M . A pilot randomized controlled trial of ketamine in Borderline Personality Disorder. Neuropsychopharmacology. 2023; 48(7):991-999. PMC: 10209175. DOI: 10.1038/s41386-023-01540-4. View

12.

Posner K, Brown G, Stanley B, Brent D, Yershova K, Oquendo M . The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011; 168(12):1266-77. PMC: 3893686. DOI: 10.1176/appi.ajp.2011.10111704. View

13.

Bahr R, Lopez A, Rey J . Intranasal Esketamine (Spravato) for Use in Treatment-Resistant Depression In Conjunction With an Oral Antidepressant. P T. 2019; 44(6):340-375. PMC: 6534172. View

14.

Zarate Jr C, Singh J, Carlson P, Brutsche N, Ameli R, Luckenbaugh D . A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006; 63(8):856-64. DOI: 10.1001/archpsyc.63.8.856. View

15.

Feeney A, Hock R, Freeman M, Flynn M, Hoeppner B, Iosifescu D . The effect of single administration of intravenous ketamine augmentation on suicidal ideation in treatment-resistant unipolar depression: Results from a randomized double-blind study. Eur Neuropsychopharmacol. 2021; 49:122-132. PMC: 8338746. DOI: 10.1016/j.euroneuro.2021.04.024. View

16.

Lin W, Su T, Li C, Wu H, Tsai S, Bai Y . Baseline cognitive function predicts full remission of suicidal symptoms among patients with treatment-resistant depression and strong suicidal ideation after low-dose ketamine infusion. J Psychopharmacol. 2023; 37(8):795-801. DOI: 10.1177/02698811231182107. View

17.

Fava M, Freeman M, Flynn M, Judge H, Hoeppner B, Cusin C . Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry. 2018; 25(7):1592-1603. PMC: 6447473. DOI: 10.1038/s41380-018-0256-5. View

18.

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

19.

Fedgchin M, Trivedi M, Daly E, Melkote R, Lane R, Lim P . Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1). Int J Neuropsychopharmacol. 2019; 22(10):616-630. PMC: 6822141. DOI: 10.1093/ijnp/pyz039. View

20.

Bandeira I, Leal G, Correia-Melo F, Souza-Marques B, Silva S, Lins-Silva D . Arketamine for bipolar depression: Open-label, dose-escalation, pilot study. J Psychiatr Res. 2023; 164:229-234. DOI: 10.1016/j.jpsychires.2023.06.028. View